Atea Pharmaceuticals, Inc. (AVIR)

Atea Pharmaceuticals' stock price increased by 107.19% over the past year and outperformed the S&P500 Index by +103.38% over the past six months. Following its Q4 2025 earnings announcement on March 5, 2026, AVIR shares gained +11.1% the next day, closing at $5.89, but drifted -9.5% lower in the subsequent 20 days. In April 2025, the company completed a stock repurchase program, buying back 7,673,793 shares at an average price of $3.26 per share.

As a clinical-stage biopharmaceutical company, Atea Pharmaceuticals is primarily focused on the research, development, and advancement of drug candidates through clinical trials, rather than the sale of approved commercial products. Therefore, information regarding demand seasonality for its products and services is not applicable at this stage of the company's development.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapeutics for serious viral infections. The company uses a proprietary nucleos(t)ide prodrug platform to develop product candidates targeting single-stranded ribonucleic acid viruses. Its major product candidates include bemnifosbuvir and ruzasvir for HCV, currently in Phase 3 clinical trials, and AT-587 for chronic HEV infection, in Phase 1 clinical trials. Atea has a license agreement with MSD International GmbH for ruzasvir.

Atea Pharmaceuticals is headquartered in Boston, Massachusetts, United States. Its clinical development programs have a global reach, with Phase 3 clinical trials for HCV being conducted in the US and Canada (C-BEYOND) and regions outside North America (C-FORWARD).

Atea Pharmaceuticals is known as a clinical-stage biopharmaceutical company focused on addressing serious viral infections through oral antiviral therapies. The ongoing global Phase 3 clinical trials for HCV and the expansion into a new HEV development program contribute to its scientific and medical standing. The strong stock performance over the past six months could be seen as a positive indicator of investor confidence. Atea Pharmaceuticals' MarketRank™ scored lower than 87% of companies evaluated in the medical sector.

Atea Pharmaceuticals has a significant institutional ownership base, including Fmr Llc, BlackRock, Inc., BML Capital Management, LLC, Tang Capital Management Llc, and Vanguard Group Inc. Institutional investors collectively hold a substantial portion of the company's stock, ranging from approximately 21.30% to 86.67%. Founder, CEO, and Chairman Jean-Pierre Sommadossi, Ph.D., holds approximately 10.10% of the shares.